Gene therapy in the management of oral cancer: Review of the literature

Medicina Oral, Patologia Oral y Cirugia Bucal

Volumn 13, Issue 1, 2008, Pages

  Ayllón Barbellido, Sonia ^c   Campo Trapero, Julián ^a,b   Cano Sánchez, Jorge ^a   Perea García, Miguel A ^a   Escudero Castaño, Nayra ^c   Bascones Martínez, Antonio ^a  

^a UCM

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c NONE

Author keywords

Gene therapy; Oral cancer; Viral vectors

Indexed keywords

ADENOVIRUS VECTOR; ADVEXIN; AKADAIC ACID; ALLOVECTIN 7; ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; CANCER VACCINE; CD137 ANTIGEN; COMPLEMENTARY RNA; DIHYDROFOLATE REDUCTASE; DOXORUBICIN; E1B PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; GANCICLOVIR; HERPES SIMPLEX VIRUS THYMIDINE KINASE PROTEIN; INTERCELLULAR ADHESION MOLECULE 2 ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 24; MANGANESE SUPEROXIDE DISMUTASE; MULTIDRUG RESISTANCE PROTEIN 1; OAS 403; ONCOLYTIC VIRUS; ONYX 015; OW 34; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ADENOVIRUS; BLOOD CLOTTING DISORDER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; CLINICAL TRIAL; DRUG FATALITY; DRUG MECHANISM; GENE THERAPY; GENE TRANSFER; HUMAN; IMMUNOTHERAPY; INFLAMMATION; MOUTH CANCER; NONHUMAN; REVIEW; SUICIDE GENE THERAPY; TUMOR SUPPRESSOR GENE;

ADENOVIRIDAE; CARCINOMA, SQUAMOUS CELL; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; HUMANS; MOUTH NEOPLASMS; ONCOLYTIC VIROTHERAPY; PRECANCEROUS CONDITIONS;

EID: 38549131208     PISSN: 16984447     EISSN: 16986946     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Sudbø J, Reith A. The evolution of predictive oncology and molecular-based therapy for oral cancer prevention. Int J Cancer. 2005 Jun 20;115(3):339-45.
2. Gottesman MM. Cancer gene therapy: an awkward adolescence. Cancer Gene Ther. 2003 Jul;10(7):501-8.
3. Xi S, Grandis JR. Gene therapy for the treatment of oral squamous cell carcinoma. J Dent Res. 2003 Jan;82(1):11-6.
4. Lopez-Martinez M, Anzola M, Cuevas N, Aguirre JM, De-Pancorbo M. Clinical applications of the diagnosis of p53 alterations in squamous cell carcinoma of the head and neck. Med Oral. 2002 Mar-Apr;7(2):108-20.
5. Wodarz D. Gene therapy for killing p53-negative cancer cells: use of replicating versus nonreplicating agents. Hum Gene Ther. 2003 Jan 20;14(2):153-9.
6. Liu TJ, Zhang WW, Taylor DL, Roth JA, Goepfert H, Clayman GL. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res. 1994 Jul 15;54(14):3662-7.
7. Wong RJ, Joe JK, Kim SH, Shah JP, Horsburgh B, Fong Y. Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to treat sites of lymphatic metastases. Hum Gene Ther. 2002 Jul 1;13(10):1213-23.
8. Supriatno, Harada K, Kawaguchi S, Onoue T, Yoshida H, Sato M. Characteristics of antitumor activity of mutant type p27Kip1 gene in an oral cancer cell line. Oral Oncol. 2004 Aug;40(7):679-87.
9. Gleich LL. Gene therapy for head and neck cancer. Laryngoscope. 2000 May;110(5 Pt 1):708-26.
10. Chahlavi A, Rabkin S, Todo T, Sundaresan P, Martuza R. Effect of prior exposure to herpes simplex virus 1 on viral vector-mediated tumor therapy in immunocompetent mice. Gene Ther. 1999 Oct;6(10):1751-8.
11. Galanis E, Okuno SH, Nascimento AG, Lewis BD, Lee RA, Oliveira AM, et al. Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther. 2005 Mar;12(5):437-45.
12. Heise C, Kirn DH. Replication-selective adenoviruses as oncolytic agents. J Clin Invest. 2000 Apr;105(7):847-51.
13. Nemunaitis J, Cunningham C, Tong AW, Post L, Netto G, Paulson AS, et al. Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Ther. 2003 May;10(5):341-52.
14. Nemunaitis J, Ganly I, Khuri F, Arseneau J, Kuhn J, McCarty T, et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res. 2000 Nov 15;60(22):6359-66.
15. Rudin CM, Cohen EE, Papadimitrakopoulou VA, Silverman S Jr, Recant W, El-Naggar AK, et al. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol. 2003 Dec 15;21(24):4546-52.
16. Hawkins LK, Lemoine NR, Kirn D. Oncolytic biotherapy: a novel therapeutic plafform. Lancet Oncol. 2002 Jan;3(1):17-26.
17. Fukui T, Hayashi Y, Kagami H, Yamamoto N, Fukuhara H, Tohnai I, et al. Suicide gene therapy for human oral squamous cell carcinoma cell lines with adeno-associated virus vector. Oral Oncol. 2001 Apr;37(3):211-5.
18. Neves SS, Sarmento-Ribeiro AB, Simões SP, Pedroso de Lima MC. Transfection of oral cancer cells mediated by transferrin-associated lipoplexes: mechanisms of cell death induced by herpes simplex virus thymidine kinase/ganciclovir therapy. Biochim Biophys Acta. 2006 Nov;1758(11):1703-12.
19. Young M, Overlid N, Konopka K, Düzgünes N. Gene therapy for oral cancer: efficient delivery of a 'suicide gene' to murine oral cancer cells in physiological milieu. J Calif Dent Assoc. 2005 Dec;33(12):967-71.
20. Cirone P, Bourgeois JM, Chang PL. Antiangiogenic cancer therapy with microencapsulated cells. Hum Gene Ther. 2003 Jul 20;14(11):1065-77.
21. Niethammer AG, Xiang R, Becker JC, Wodrich H, Pertl U, Karsten G, et al. A dna vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med. 2002 Dec;8(12):1369-75.
22. Tamatani T, Azuma M, Ashida Y, Motegi K, Takashima R, Harada K, et al. Enhanced radiosensitization and chemosensitization in NF-kappaB-suppressed human oral cancer cells via the inhibition of gamma-irradiation- and 5-FU-induced production of IL-6 and IL-8. Int J Cancer. 2004 Mar 1;108(6):912-21.
23. Shillitoe EJ. Papillomaviruses as targets for cancer gene therapy. Cancer Gene Ther. 2006 May;13(5):445-50.
24. Dehari H, Ito Y, Nakamura T, Kobune M, Sasaki K, Yonekura N, et al. Enhanced antitumor effect of RGD fiber-modified adenovirus for gene therapy of oral cancer. Cancer Gene Ther. 2003 Jan;10(1):75-85.
25. Perez OD, Kinoshita S, Hitoshi Y, Payan DG, Kitamura T, Nolan GP, et al. Activation of the PKB/AKT pathway by ICAM-2. Immunity. 2002 Jan;16(1):51-65.
26. Imboden M, Shi F, Pugh TD, Freud AG, Thom NJ, Hank JA, et al. Safety of interleukin-12 gene therapy against cancer: a murine biodistribution and toxicity study. Hum Gene Ther. 2003 Jul 20;14(11):1037-48.
27. Okamura H, Morimoto H, Fujita M, Nasu F, Sasakia E, Haneji T. Suppression of Egr-1 expression in human oral squamous carcinoma cells by okadaic acid. Oral Oncol. 2002 Dec;38(8):779-84.
28. Bertrand JR, Pottier M, Vekris A, Opolon P, Maksimenko A, Malvy C. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun. 2002 Aug 30;296(4):1000-4.
29. Waters JS, Webb A, Cunningham D, Clarke PA, Raynaud F, Di Stefano F, et al. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol. 2000 May;18(9):1812-23.
30. Smith AE. Viral vectors in gene therapy. Annu Rev Microbiol. 1995;49:807-38.